1 / 10

TBD-UK: The UK response in the discovery and development of new TB drugs.

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB New Tools meeting HoC 23 rd June 2011. www.tbd-uk.org.uk. Why are we here today?. We all know the facts and figures about TB

wilbur
Download Presentation

TBD-UK: The UK response in the discovery and development of new TB drugs.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB New Tools meeting HoC 23rd June 2011 www.tbd-uk.org.uk

  2. Why are we here today? • We all know the facts and figures about TB • New tools urgently required: • Rapid, robust, reliable & accurate diagnostics • Vaccines • Key Biomarkers • New drugs

  3. Why new TB drugs? • Treatment takes 6 to 9 months • Contributes to low compliance, resistance and relapse • Co-infection with HIV/AIDS is limits the use of current drugs • No new drugs since the 1960s! • New drugs urgently needed to reduce treatment time, combat resistance and be compatible with HIV/AIDS sufferers

  4. The Challenge ! Broad spectrum antibiotics Drug regime for drug susceptible TB

  5. State of the current development pipeline • Long & Very complex with high rates of attrition • Highly multi disciplinary • Very expensive - £100s millions • No commercial market to sustain the development pipeline • Current strategy: • TB Alliance is the “Global Coordinator” working with partners in academia and pharmaceutical industry • UK can increase its’ established role within this strategy

  6. State of the current Global development pipeline Start Finish Progressing BUT grossly insufficient

  7. The UK perspective: TB Drug discovery UK (TBD-UK) • Funded for 2 years in 2009 by the Medical Research Council • UK wide consortia of academic and industrial partners involved in TB drug discovery and development research • Goal: To engage the UK in coordinated research and maximise it’s contribution to global efforts to facilitate drug development and provide new drugs at the clinic

  8. TBD-UK: What has been achieved so far? • New class of anti-TB agent identified (others now integrated into TBD-UK) • New basic science breakthrough discoveries in drug targets • IMI-EU framework 7 pre-DICT consortia formed to support “models” • Working TBD-UK blueprint created to guide all UK research • Significant UK outreach with 40+ researchers engaged in collaboration • International outreach via website www.tbd-uk.org.uk

  9. TBD-UK: Conclusion & Future direction • UK science ready to integrate with DFID & BIS policy to make real impact • Development of public private partnerships is a key factor • Dialogue with pharmaceutical industry, MRC, NGOs, Charities and DFID essential to move forward and maximise UK potential • APPG-TB round table meeting with all parties should be the next step to achieve our common goals in finding new TB drugs

More Related